866-997-4948(US-Canada Toll Free)

Candidiasis - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Diseases & Conditions

No. of Pages : 112 Pages


This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Candidiasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Candidiasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Candidiasis Overview 10
Therapeutics Development 11
Pipeline Products for Candidiasis Overview 11
Pipeline Products for Candidiasis Comparative Analysis 12
Candidiasis Therapeutics under Development by Companies 13
Candidiasis Therapeutics under Investigation by Universities/Institutes 15
Candidiasis Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Candidiasis Products under Development by Companies 20
Candidiasis Products under Investigation by Universities/Institutes 21
Candidiasis Companies Involved in Therapeutics Development 22
Sequella, Inc. 22
Daiichi Sankyo Company, Limited 23
Merck & Co., Inc. 24
Novartis AG 25
Eisai Co., Ltd. 26
iCo Therapeutics Inc. 27
Almirall, S.A. 28
Basilea Pharmaceutica AG 29
Pacgen Life Science Corporation 30
NovaDigm Therapeutics, Inc. 31
Cellceutix Corporation 32
Aureogen Biosciences, Inc. 33
Sealife PHARMA GMBH 34
Panacela Labs, Inc. 35
Biomar Microbial Technologies 36
Candidiasis Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
posaconazole - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
isavuconazonium - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PAC-113 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
LAS-41003 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NDV-3 Vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
SQ-109 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
PMX-30016 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
amphotericin B - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
E-1210 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
SLP-0901 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
D11-2040 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Xenomycin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
AUGC-15 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Compound-18545 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Compound-9403 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PMX-1502 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
PMX-519 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Candida Vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
PMX-1408 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
E-1211 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SLP-1002 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
SLP-0907 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Drugs for Fungal Infections - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules for Candidiasis - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Compound-14844 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Program For Women Health - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PMX-70004 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
PMX-1570 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PMX-1576 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PMX-1591 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
PMX-1625 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules for Aspergillosis and Candidiasis - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules for Candidiasis - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Drugs for Fungal Infections - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
PAC-113 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Candidiasis Recent Pipeline Updates 89
Candidiasis Dormant Projects 99
Candidiasis Discontinued Products 100
Candidiasis Product Development Milestones 101
Featured News & Press Releases 101
Mar 14, 2014: FDA Approves Mercks NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use 101
Nov 18, 2013: Cellceutix Identifies PMX-1408 as treatment Gram-Negative and Candida Fungal Infections 102
Nov 18, 2013: Cellceutix Identifies Drug Candidate for Candida Fungal Infections 102
Nov 18, 2013: Mercks New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL (posaconazole) Receives FDA Priority Review 103
Sep 13, 2013: Basilea reports presentation of posters at ICAAC on investigational anti-infective isavuconazole 105
Jul 17, 2013: Basilea provides update on isavuconazole phase 3 program 107
Jun 24, 2013: FDA Approves Pediatric Indication For Astellas\'s Mycamine For Injection 107
Apr 29, 2013: Basilea Pharma Presents Data On Anti-fungal Drug Candidate Isavuconazole At ECCMID 2013 108
Apr 10, 2013: Merck Announces FDA Acceptance Of NDA For Investigational Tablet Formulation Of Antifungal Noxafil 109
Dec 13, 2012: NovaDigm Announce Publication Of Positive Phase I Study Data Of NDV-3 Vaccine For Candida And Staph Infections In Vaccine Journal 110

Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 112
Disclaimer 112

List of Table


Number of Products under Development for Candidiasis, H1 2014 11
Number of Products under Development for Candidiasis Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Investigation by Universities/Institutes, H1 2014 21
Candidiasis Pipeline by Sequella, Inc., H1 2014 22
Candidiasis Pipeline by Daiichi Sankyo Company, Limited, H1 2014 23
Candidiasis Pipeline by Merck & Co., Inc., H1 2014 24
Candidiasis Pipeline by Novartis AG, H1 2014 25
Candidiasis Pipeline by Eisai Co., Ltd., H1 2014 26
Candidiasis Pipeline by iCo Therapeutics Inc., H1 2014 27
Candidiasis Pipeline by Almirall, S.A., H1 2014 28
Candidiasis Pipeline by Basilea Pharmaceutica AG, H1 2014 29
Candidiasis Pipeline by Pacgen Life Science Corporation, H1 2014 30
Candidiasis Pipeline by NovaDigm Therapeutics, Inc., H1 2014 31
Candidiasis Pipeline by Cellceutix Corporation, H1 2014 32
Candidiasis Pipeline by Aureogen Biosciences, Inc., H1 2014 33
Candidiasis Pipeline by Sealife PHARMA GMBH, H1 2014 34
Candidiasis Pipeline by Panacela Labs, Inc., H1 2014 35
Candidiasis Pipeline by Biomar Microbial Technologies, H1 2014 36
Assessment by Monotherapy Products, H1 2014 37
Number of Products by Stage and Target, H1 2014 40
Number of Products by Stage and Mechanism of Action, H1 2014 43
Number of Products by Stage and Route of Administration, H1 2014 45
Number of Products by Stage and Molecule Type, H1 2014 47
Candidiasis Therapeutics Recent Pipeline Updates, H1 2014 89
Candidiasis Dormant Projects, H1 2014 99
Candidiasis Discontinued Products, H1 2014 100

List of Chart


Number of Products under Development for Candidiasis, H1 2014 11
Number of Products under Development for Candidiasis Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 37
Number of Products by Top 10 Target, H1 2014 38
Number of Products by Stage and Top 10 Target, H1 2014 39
Number of Products by Top 10 Mechanism of Action, H1 2014 41
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 42
Number of Products by Top 10 Route of Administration, H1 2014 44
Number of Products by Stage and Top 10 Route of Administration, H1 2014 45
Number of Products by Top 10 Molecule Type, H1 2014 46
Number of Products by Stage and Top 10 Molecule Type, H1 2014 47

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *